<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02371850</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00059146</org_study_id>
    <nct_id>NCT02371850</nct_id>
  </id_info>
  <brief_title>Transdermal Patch CVD 1000: The Effect of Heat on Nicotine Release From Nicotine Patches in Adult Smokers</brief_title>
  <official_title>Determination of Plasma Nicotine Levels After Using Reference and Generic Transdermal Nicotine Patches With and Without Standardized Heat Application in Adult Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Food and Drug Administration (FDA)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-dose, Open-label, Non-Randomized, 2-way Crossover Bioequivalence Study to&#xD;
      compare nicotine release after heating of a brand name (Nicoderm CQ) and generic (Aveva skin&#xD;
      patch) nicotine skin patches in adult smokers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This research study is intended to determine the effect of heat on FDA-approved nicotine&#xD;
      transdermal patches and whether the heat applied will result in more nicotine being absorbed&#xD;
      through the skin than without applying heat. This is important given that little is known&#xD;
      about how the release of nicotine is affected by heat, particularly for generic products that&#xD;
      are also available over the counter. This study will use nicotine patches (brand name and&#xD;
      generic patches) that have been approved by the Food and Drug Administration (FDA) and are&#xD;
      already sold over the counter to customers in the United States, and will not include any&#xD;
      placebos.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Each subjects gets two procedure days with heating applied for one hour at hours 4 and hour 8 after the application of the Nicoderm CQ nicotine patch, then followed by two procedure days with heating applied for one hour at hours 4 and hour 8, after the application of the Aveva nicotine patch (total of four Procedure days)</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of Maximum Serum Concentration (Cmax)</measure>
    <time_frame>four procedure days for each participant</time_frame>
    <description>The main outcome measure of the study is the measurement of maximum serum concentration (Cmax)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>0-12 h for each of the four procedure day</time_frame>
    <description>(area under the concentration-time curve of nicotine 0-12 h)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Smoking</condition>
  <arm_group>
    <arm_group_label>Nicoderm patch first, then Aveva patch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject gets two procedure days with heating applied for one hour at hours 4 and hour 8 after the application of the Nicoderm CQ nicotine patch, then followed by two procedure days with heating applied for one hour at hours 4 and hour 8, after the application of the Aveva nicotine patch (total of four Procedure days)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicoderm patch first, then Aveva patch</intervention_name>
    <description>This is a single group assignment where each of 10 adult smokers completes 4 procedure days using a Nicoderm CQ nicotine patch (2 days) followed by the application of a generic Aveva patch (2 days). For each patch, heating is applied for one hour at hour 4 on the first procedure day and at hour 8 in the second procedure day (2 days per patch, or a total of 4 days per subject).</description>
    <arm_group_label>Nicoderm patch first, then Aveva patch</arm_group_label>
    <other_name>Brand name nicotine patch first, then generic nicotine patch</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Men or non-pregnant women of any ethnic background between the age of 18 and 45&#xD;
             years old&#xD;
&#xD;
          -  2. Subjects should be cigarette smokers who smoke at least 5 cigarettes per day for&#xD;
             one year or more.&#xD;
&#xD;
          -  3. Provide written informed consent before initiation of any study procedures.&#xD;
&#xD;
          -  4. Available for follow-up for the planned duration of the study&#xD;
&#xD;
          -  5. Able to communicate well with the investigators&#xD;
&#xD;
          -  6. Able to adhere to the study restrictions and examination schedule.&#xD;
&#xD;
          -  7. Subjects who are within their ideal body weight (BMI &gt;17 and &lt;= 25)&#xD;
&#xD;
          -  8. Demonstrate comprehension of the protocol procedures and knowledge of study by&#xD;
             passing (&gt;70% correct responses) a written examination containing 20 multiple choice&#xD;
             and true false questions covering all aspects of the study including the purpose,&#xD;
             procedures, risks and benefits.&#xD;
&#xD;
          -  9. Subjects deemed to be eligible as judged by the Medically Accountable Investigator&#xD;
             (MAI) and determined by medical history, physical examination, and medication history.&#xD;
&#xD;
          -  10. Have a normal blood pressure (systolic: 90-140 mmHg; diastolic: 50-90 mmHg) and&#xD;
             heart rate (55-100 bpm),&#xD;
&#xD;
          -  11. Have normal screening laboratories for WBC, Hgb, platelets, sodium, potassium,&#xD;
             chloride, bicarbonate, BUN, creatinine, ALT and AST&#xD;
&#xD;
          -  12. Have normal screening laboratories for urine protein and urine glucose.&#xD;
&#xD;
          -  13. Female subjects must be of non-childbearing potential (as defined as surgically&#xD;
             sterile [i.e. history of hysterectomy or tubal ligation] or postmenopausal for more&#xD;
             than 1 year), or if of childbearing potential, must be non-pregnant at the time of&#xD;
             enrollment and on the morning of each procedure day, and must agree to use hormonal or&#xD;
             barrier birth control such as implants, injectables, combined oral contraceptives,&#xD;
             some intrauterine devices (IUDs), sexual abstinence, or a vasectomized partner.&#xD;
&#xD;
          -  14. Agrees not to participate in another clinical study during the study period.&#xD;
&#xD;
          -  15. Agrees not to donate blood to a blood bank throughout participation in the study&#xD;
             and for at least 3 months after last procedure day.&#xD;
&#xD;
          -  16. Have a normal ECG&#xD;
&#xD;
          -  17. Be a smoker willing to refrain from smoking 10 hours prior to, and during, each&#xD;
             procedure day of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Subjects who are nonsmokers or smoke less than 5 cigarettes per day&#xD;
&#xD;
          -  2. Women who are pregnant or lactating or have a positive serum pregnancy test at&#xD;
             enrollment or on the morning of any procedure day.&#xD;
&#xD;
          -  3. Participation in any ongoing investigational drug trial or clinical drug trial&#xD;
&#xD;
          -  4. Abnormal Vital signs, defined as:&#xD;
&#xD;
               -  Hypertension (systolic blood pressure &gt;140 mm Hg or diastolic blood pressure &gt;90&#xD;
                  mm Hg) at rest on 2 separate days)&#xD;
&#xD;
               -  Heart rate &lt;55 at rest on 2 separate days&#xD;
&#xD;
               -  Respiratory rate &gt;20&#xD;
&#xD;
          -  5. Temperature &gt; 38.0 ºC (100.4 ºF) or symptoms of an acute self-limited illness such&#xD;
             as an upper respiratory infection or gastroenteritis within 7 days of administration&#xD;
             of the transdermal patch.&#xD;
&#xD;
          -  6. Active positive Hepatitis B, C, and HIV serologies&#xD;
&#xD;
          -  7. Positive urine drug screening test&#xD;
&#xD;
          -  8. Use of any prescription medication during the period 0 to 30 days or over-the&#xD;
             counter medication (vitamin, herbal supplements and birth control medications not&#xD;
             included) during the period 0 to 5 days before entry to the study&#xD;
&#xD;
          -  9. Donation or loss of greater than one pint of blood within 60 days of entry to the&#xD;
             study&#xD;
&#xD;
          -  10. Any prior serious adverse reaction or hypersensitivity to nicotine or any of the&#xD;
             inactive ingredients in the patch (acrylate adhesive, polyester, silicone, ethylene&#xD;
             vinyl acetate-copolymer polyisobutylene and polyethylene)&#xD;
&#xD;
          -  11. Have a diagnosis of schizophrenia or other major psychiatric diagnosis.&#xD;
&#xD;
          -  12. Received an experimental agent (vaccine, drug, biologic, device, blood product or&#xD;
             medication) within 1 month before enrollment in this study or expects to receive an&#xD;
             experimental agent during the study.&#xD;
&#xD;
          -  13. Any condition that would, in the opinion of the Medically Accountable Investigator&#xD;
             (MAI), place the subject at an unacceptable risk of injury or render the subject&#xD;
             unable to meet the requirements of the protocol.&#xD;
&#xD;
          -  14. Inability to communicate or co-operate with the investigators&#xD;
&#xD;
          -  15. History of consumption of alcohol within 24 hours prior to dose administration&#xD;
&#xD;
          -  16. Scarring on upper arms, including tattoos at planned site of patch placement&#xD;
             making skin reactions not evaluable&#xD;
&#xD;
          -  17. Subject who currently has any of the following conditions:&#xD;
&#xD;
               1. Thrombophlebitis, thromboembolic disorders&#xD;
&#xD;
               2. A past history of deep vein thrombophlebitis or thromboembolic disorders&#xD;
&#xD;
               3. Cerebrovascular or coronary artery disease (current or past history)&#xD;
&#xD;
               4. Valvular heart disease with complications&#xD;
&#xD;
               5. Severe hypertension&#xD;
&#xD;
               6. Diabetes with vascular involvement&#xD;
&#xD;
               7. Headaches with focal neurological symptoms&#xD;
&#xD;
               8. Major surgery with prolonged immobilization&#xD;
&#xD;
          -  18. Medical history of a serious chronic condition (e.g. allergic conditions such as&#xD;
             anaphylaxis, asthma or generalized drug reaction).&#xD;
&#xD;
          -  19. Medical history of significant dermatologic diseases or conditions, such as atopy,&#xD;
             psoriasis, vitiligo or conditions known to alter skin appearance or physiologic&#xD;
             response (e.g. diabetes, porphyria).&#xD;
&#xD;
          -  20. History of significant dermatologic cancers (e.g. melanoma, squamous cell&#xD;
             carcinoma), except basal cell carcinomas that were superficial and did not involve the&#xD;
             investigative site.&#xD;
&#xD;
          -  21. Within 10 hours prior to dosing, use of other nicotine products (e.g. nicotine gum&#xD;
             or other nicotine-containing products) that would significantly influence or&#xD;
             exaggerate responses to the nicotine patches used in this study.&#xD;
&#xD;
          -  22. Within 72 hours prior to dosing, use of antihistamines or use of topical drugs at&#xD;
             patch site.&#xD;
&#xD;
          -  23. Subject has an obvious difference in skin color between arms or the presence of a&#xD;
             skin condition, open sores, scar tissue, tattoo, or coloration that would interfere&#xD;
             with placement of test articles, skin assessment, or reactions to drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samer El-Kamary, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland, Baltimore</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Maryland, Baltimore Center for Vaccine Development</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>February 6, 2015</study_first_submitted>
  <study_first_submitted_qc>February 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2015</study_first_posted>
  <results_first_submitted>April 11, 2017</results_first_submitted>
  <results_first_submitted_qc>July 18, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 17, 2017</results_first_posted>
  <last_update_submitted>June 14, 2021</last_update_submitted>
  <last_update_submitted_qc>June 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland, Baltimore</investigator_affiliation>
    <investigator_full_name>Audra Stinchcomb</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Therapeutic Equivalency</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>IPD will not be shared</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Nicoderm Patch First, Then Aveva Patch</title>
          <description>Each subjects gets two procedure days with heating applied for one hour at hours 4 and hour 8 after the application of the Nicoderm CQ nicotine patch, then followed by two procedure days with heating applied for one hour at hours 4 and hour 8, after the application of the Aveva nicotine patch (total of four Procedure days)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nicoderm Patch First, Then Aveva Patch</title>
          <description>Each subjects gets two procedure days with heating applied for one hour at hours 4 and hour 8 after the application of the Nicoderm CQ nicotine patch, then followed by two procedure days with heating applied for one hour at hours 4 and hour 8, after the application of the Aveva nicotine patch (total of four Procedure days)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29" spread="6.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Measurement of Maximum Serum Concentration (Cmax)</title>
        <description>The main outcome measure of the study is the measurement of maximum serum concentration (Cmax)</description>
        <time_frame>four procedure days for each participant</time_frame>
        <population>Ten adult smokers between 24 and 44 years of age at the time of enrollment completed the study. The clinical study was an single-group, open-label study. Each subject completed 4 study visits where in-vivo nicotine levels were measured using a reference patch (Nicoderm CQ) and a generic patch (Aveva)</population>
        <group_list>
          <group group_id="O1">
            <title>Nicoderm Patch First, Then Aveva Patch</title>
            <description>Each subjects gets two procedure days with heating applied for one hour at hours 4 and hour 8 after the application of the Nicoderm CQ nicotine patch, then followed by two procedure days with heating applied for one hour at hours 4 and hour 8, after the application of the Aveva nicotine patch (total of four Procedure days)</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of Maximum Serum Concentration (Cmax)</title>
          <description>The main outcome measure of the study is the measurement of maximum serum concentration (Cmax)</description>
          <population>Ten adult smokers between 24 and 44 years of age at the time of enrollment completed the study. The clinical study was an single-group, open-label study. Each subject completed 4 study visits where in-vivo nicotine levels were measured using a reference patch (Nicoderm CQ) and a generic patch (Aveva)</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NicoDerm CQ early heat serum nicotine Cmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.47" spread="10.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aveva early heat serum nicotine Cmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.32" spread="13.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NicoDerm CQ late heat serum nicotine Cmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.04" spread="8.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aveva late heat serum nicotine Cmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.96" spread="9.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC</title>
        <description>(area under the concentration-time curve of nicotine 0-12 h)</description>
        <time_frame>0-12 h for each of the four procedure day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NicoDerm CQ (Early Heat)</title>
            <description>early heat</description>
          </group>
          <group group_id="O2">
            <title>NicoDerm CQ (Late Heat)</title>
            <description>late heat</description>
          </group>
          <group group_id="O3">
            <title>Aveva (Early Heat)</title>
            <description>early heat</description>
          </group>
          <group group_id="O4">
            <title>Aveva (Late Heat)</title>
            <description>late heat</description>
          </group>
        </group_list>
        <measure>
          <title>AUC</title>
          <description>(area under the concentration-time curve of nicotine 0-12 h)</description>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="173.8" spread="54.10"/>
                    <measurement group_id="O2" value="184.3" spread="67.92"/>
                    <measurement group_id="O3" value="116.3" spread="73.41"/>
                    <measurement group_id="O4" value="121.20" spread="49.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <desc>The definition does not differ.</desc>
      <group_list>
        <group group_id="E1">
          <title>Nicoderm Patch 4 h Heat Application</title>
          <description>Each subjects gets two procedure days with heating applied for one hour at hours 4 and hour 8 after the application of the Nicoderm CQ nicotine patch, then followed by two procedure days with heating applied for one hour at hours 4 and hour 8, after the application of the Aveva nicotine patch (total of four Procedure days)</description>
        </group>
        <group group_id="E2">
          <title>Nicoderm Patch 8 h Heat Application</title>
          <description>Each subjects gets two procedure days with heating applied for one hour at hours 4 and hour 8 after the application of the Nicoderm CQ nicotine patch, then followed by two procedure days with heating applied for one hour at hours 4 and hour 8, after the application of the Aveva nicotine patch (total of four Procedure days)</description>
        </group>
        <group group_id="E3">
          <title>Aveva Patch 4 h Heat Application</title>
          <description>Each subjects gets two procedure days with heating applied for one hour at hours 4 and hour 8 after the application of the Nicoderm CQ nicotine patch, then followed by two procedure days with heating applied for one hour at hours 4 and hour 8, after the application of the Aveva nicotine patch (total of four Procedure days)</description>
        </group>
        <group group_id="E4">
          <title>Aveva Patch 8 h Heat Application</title>
          <description>Each subjects gets two procedure days with heating applied for one hour at hours 4 and hour 8 after the application of the Nicoderm CQ nicotine patch, then followed by two procedure days with heating applied for one hour at hours 4 and hour 8, after the application of the Aveva nicotine patch (total of four Procedure days)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Elevated systolic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Heat rash</sub_title>
                <description>due to heating pad application</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Numbness</sub_title>
                <description>(transient) right thumb</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Skin redness</sub_title>
                <description>TDS site (due to external heat application)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Respiratory Rate</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema at the site of patch placement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hyperpigmentation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <description>at IV site</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <description>pruritus at patch application site</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Restricted until the manuscript is published in a peer-reviewed journal.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Audra Stinchcomb, PharmD</name_or_title>
      <organization>University of Maryland School of Pharmacy</organization>
      <phone>410-706-2646</phone>
      <email>astinchc@rx.umaryland.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

